The Science Behind Our Novel Particles

Faster, Lower Cost Trials With Increased Visibility and Accuracy

 

Applications

Based on nanoparticle technology, our distinctive engineered platform has been used in a variety of biomedical applications. In cancer, NanoMedtrix material has been designed to target solid tumors such as: bladder, colorectal and neural tumors. The same nano-compounds are adjustable to provide valuable information on the disease process of multitude illnesses. What makes our approach unique is that target can be validated non-invasively and sequentially by microscopic and scanning methods without the need for further injections. This will lead to optimized prognostics.

To enhance whole live animal studies, we have performed extensive characterization of our products and toxicology evaluation (with live cells and with adult and fetal laboratory animals).  Currently, we are focusing efforts on the preclinical products which allows validation and acceptance thought the scientific community. Our long term vision is to provide our products to physicians for clinical applications.

We provide an invaluable set of patent-pending multi-scale tools for research into early detection and treatment of diseases, with the goal of achieving greater cost effectiveness in medical care through early, accurate and rapid diagnosis followed by successful interventions.  Specifics of our science include sequential detection / quantification:  

 

Flourescence

Mesenchymal stem cell labeled with MSN particles confocal microscopy florescent labeling

 

Magentic Resonance Imaging (MRI)

3-dimensional MRI "virtual cytoscopy" of a mouse bladder (gray) containing a tumor (red) labeled with NanoMedTrix MSN particles.  The particles improve the definition of the tumor boundaries and even show tumor growth within the bladder wall, important for tumor grading.

 

Echographic Ultrasound

Echo of injected heart and 3D imaging.  Rapid image guiding information. 

 

Life Science:  Quantitative Measurements

Characterization of lanthanide contrast agents using MRI phantoms containing the indicated concentrations of material.

 

References

 

Crich, S. G.; Biancone, L.; Cantaluppi, V.; Duo, D.; Esposito, G.; Russo, S.; Camussi, G.; Aime, S. Magn. Reson. Med. 2004, 51, 938-944.

Diamente, P. R.; van Veggel, F. C. J. Fluoresc. 2005, 15, 543-551.

Giri, S.; Trewyn, B. G.; Stellmaker, M. P.; Lin, V. S. Angew. Chem. Int. Ed Engl. 2005, 44, 5038-5044.

Goldys, E. M.; Drozdowicz-Tomsia, K.; Jinjun, S.; Dosev, D.; Kennedy, I. M.; Yatsunenko, S.; Godlewski, M. J. Am. Chem. Soc. 2006, 128, 14498-14505.

Gruenhagen, J. A.; Lai, C. Y.; Radu, D. R.; Lin, V. S.; Yeung, E. S. Appl. Spectrosc. 2005, 59, 424-431.

Slowing, I.; Trewyn, B. G.; Lin, V. S. J. Am. Chem. Soc. 2006, 128, 14792-14793.

Slowing, I. I.; Trewyn, B. G.; Lin, V. S. J. Am. Chem. Soc. 2007, 129, 8845-8849.REFERENCES